Marco is Chief Scientific Officer and Co-Founder of AI-enabled causal modelling company, biotx.ai. Prior to his focus on utilising AI technology to enhance clinical research, Marco had an exceptional academic career, winning Best PhD of the year award in Chemistry in his home country Germany before doing a Post-Doc at the University of Cambridge.
During his time at Cambridge, Marco received a Marie-Curie fellowship, as well as a stipend from the Gates Foundation to do his own research. Working with people like Chris Abell and Tom Blundell opened his eyes to the possibilities of launching his own company, as well as to the limitation of traditional approaches to drug development: The inability to predict clinical efficacy. Solving this problem became the mission of biotx.ai.
